ニューロモジュレーション市場：技術別、用途別-2024-2030年の世界予測

ニューロモジュレーション市場規模は2023年に77億6,000万米ドルと推計され、2024年には86億1,000万米ドルに達し、CAGR 11.50％で2030年には166億2,000万米ドルに達すると予測されています。

ニューロモジュレーションデバイスと治療法は、神経系の活動を調節するために、電気的、化学的、または医薬的な薬剤を神経系に送達するように設計されています。この技術は主に、慢性疼痛、てんかん、パーキンソン病、尿失禁など、さまざまな疾患の治療に用いられます。慢性疼痛や神経疾患の増加が、ニューロモジュレーション治療に対する緊急のニーズを生み出しています。さらに、ニューロモジュレーション技術の利点に関する意識の高まり、ヘルスケア支出の増加、神経学的治療へのアクセスを促進する政府の取り組みが、ニューロモジュレーションの採用拡大に寄与しています。しかし、ニューロモジュレーション機器やシステムの製品回収が発生し、安全性や健康上のリスクの可能性が、この技術の普及を妨げています。さらに、医療機器の承認に関する厳しい規制と相まって、治療の侵襲性がニューロモジュレーション戦略の採用を遅らせる可能性があります。しかし、主要企業は、患者への適用範囲を拡大し、患者のコンプライアンスを維持するために、非侵襲的な方法を調査しています。個別化されたニューロモジュレーション療法を開発することで、個々の患者のニーズや生理学に対応し、より優れた治療結果を提供できる可能性があります。生体適合材料の進歩、ニューロモジュレーションデバイスを制御するためのワイヤレス技術の導入、ニューロモジュレーションの結果を解釈するためのビッグデータ解析の活用は、この技術の成長に新たな機会をもたらす可能性があります。

テクノロジー運動障害や精神疾患に対する脳深部刺激療法へのニーズの高まり

脳深部刺激療法（DBS）は、パーキンソン病、本態性振戦、ジストニアなどの運動障害を対象とした治療法です。脳の特定の領域に電極を埋め込み、異常なインパルスを制御する電気インパルスを発生させる。DBSの必要性は、一般に重症度と他の治療に対する反応性に基づいて判断されます。胃刺激療法は胃電気刺激療法（GES）とも呼ばれ、胃の筋肉と神経を標的とし、通常、肥満や胃不全麻痺の治療に用いられます。患者が従来の治療法に反応せず、症状や体重を管理するために代替的な介入を必要とする場合に、その必要性が生じる。仙骨神経刺激は主に尿失禁や便失禁の治療に用いられます。保存的治療で十分な効果が得られない失禁患者は、植え込み可能な装置を用いて仙骨神経を電気刺激するSNSの候補となります。脊髄刺激は、腰痛手術失敗症候群、複合性局所疼痛症候群、慢性難治性疼痛などの慢性疼痛に対する治療戦略です。SCSは、他の疼痛管理療法で十分な緩和が得られない場合に選択されます。脊髄に低電圧の電気刺激を与え、痛みの信号が脳に到達する前に遮断します。迷走神経刺激は主にてんかんやうつ病の治療に用いられます。VNSは、手術に適さない患者や薬物療法に抵抗性のある患者を対象としています。この治療法は迷走神経に電気インパルスを送り、神経伝達を調節します。

応用例世界中で増加するパーキンソン病

慢性疼痛治療は、ニューロモジュレーションの主要な応用分野のひとつです。脊髄刺激装置（SCS）のような装置は、脊髄に電気インパルスを送ることで痛みを大幅に緩和することができます。薬理学的治療の限界と長期的なオピオイドの使用を避けたいという願望から、ニーズに基づいた嗜好が生まれます。ジストニアに対するニューロモジュレーションでは、不随意筋収縮を軽減するために脳深部刺激（DBS）を行うことが多いです。患者の嗜好は、手技の安全性と薬物療法が十分でない場合の症状改善の可能性に依存しています。本態性振戦は、振戦症状を抑制するために視床を標的としたDBSシステムで対処するのが一般的です。このようなシステムの必要性は、薬物療法に反応しない患者の間で高まっています。胃排出遅延を特徴とする胃不全麻痺は、胃電気刺激によって治療することができます。強迫性障害（OCD）は、従来の治療に反応しない患者に対して、その障害に関連する脳領域をターゲットとするDBSで管理することができます。ニューロモジュレーションによるパーキンソン病治療では、主にDBSが用いられ、硬直、徐脈、振戦などの症状を緩和することができます。薬物療法を行っても運動症状が改善しない場合に選択されます。難治性てんかんに対するニューロモジュレーションには、迷走神経刺激療法（VNS）と反応性神経刺激療法（RNS）があります。これらの治療法は、手術に適さない患者や難治性てんかんの患者に適応となります。治療抵抗性うつ病（TRD）には迷走神経刺激が有効であり、気分や感情の調節経路の調節に役立ちます。複数の抗うつ薬で十分な臨床効果が得られない場合に選択されます。仙骨のニューロモジュレーションは尿失禁や便失禁の管理に有効であり、有効な医薬品の選択肢が限られているため、受け入れが増加しています。

地域別インサイト

米国とカナダを中心とするアーキテクチャ地域は、強固なヘルスケアアーキテクチャと有利な償還・保険政策が特徴であり、これがニューロモジュレーション技術の採用を形成しています。さらに、この地域では神経疾患や精神衛生問題に対する意識が高く、患者の間でこの技術が認知される原動力となっています。患者の状況は、FDA認可の革新的な治療法を好み、新しい技術を採用する意欲を反映しています。南北アメリカ地域では、企業や研究機関がニューロモジュレーション治療の有効性と適用範囲の拡大を目指しているため、ニューロモジュレーション分野への継続的な研究や多額の投資が行われており、強固な特許状況を示しています。欧州連合（EU）では、平均寿命の延伸と有利な償還政策がニューロモジュレーション市場のニーズを促進する重要な要因となっています。患者のニーズは高齢化社会に蔓延する慢性疾患の管理が中心であり、顧客の購買行動は公的医療制度が提供するヘルスケア保険の影響を受けています。市場へのアクセスを容易にし、患者の安全性を確保するために、EU全域で共通の基準や規制を設けることに重点が置かれています。EUは厳格なヘルスケア規制を特徴としており、これがニューロモジュレーション技術の安全性と精度を向上させるための技術革新を後押ししています。インドや中国などの国々では神経疾患が増加しており、日本では急速に高齢化が進んでいるため、ニューロモジュレーション治療に対するニーズが高まっています。ヘルスケアの意識向上や医療インフラの整備に向けた政府の取り組みが、APAC地域におけるニューロモジュレーションの成長を後押ししています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはニューロモジュレーション市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、ニューロモジュレーション市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.ニューロモジュレーション市場の市場規模および予測は？

2.ニューロモジュレーション市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.ニューロモジュレーション市場の技術動向と規制枠組みは？

4.ニューロモジュレーション市場における主要ベンダーの市場シェアは？

5.ニューロモジュレーション市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で高齢化が進み、神経疾患が蔓延している
    • 神経刺激システムとソリューションに関する調査イニシアチブと臨床試験
    • 神経疾患や障害に対する治療法へのアクセス拡大に向けた政府の取り組み
  • 抑制要因
    • ニューロモジュレーションおよび神経刺激装置またはシステムの製品リコールの発生件数
  • 機会
    • ニューロモジュレーション戦略の効率と安全性を最適化するイノベーション
    • 世界中でニューロモジュレーションデバイスと治療法の承認が進行中
  • 課題
    • 技術の侵襲性と技術的限界
• 市場セグメンテーション分析
  • テクノロジー：運動障害や精神疾患に対する脳深部刺激療法の必要性が高まっている
  • 応用：世界中でパーキンソン病の発症率が上昇
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 ニューロモジュレーション市場：技術別

• 脳深部刺激療法
• 胃刺激
• 仙骨神経刺激
• 脊髄刺激
• 迷走神経刺激

第7章 ニューロモジュレーション市場：用途別

• 慢性の痛み
• ジストニア
• 本態性振戦
• 胃不全麻痺
• 強迫性障害
• パーキンソン病
• 難治性てんかん
• 治療抵抗性うつ病
• 尿失禁

第8章 南北アメリカのニューロモジュレーション市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域のニューロモジュレーション市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのニューロモジュレーション市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • GrayMatters Healthが米国でFDA承認の新しい自己神経調節PTSD治療法を開始
  • ドクター・レディーズがインドで片頭痛管理用ウェアラブルを発表
  • ガルデルマ、リキッドライブイベントでニューロモジュレーションの大胆な野望を発表
• 戦略分析と提言

第12章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. NEUROMODULATION MARKET RESEARCH PROCESS
• FIGURE 2. NEUROMODULATION MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NEUROMODULATION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. NEUROMODULATION MARKET DYNAMICS
• FIGURE 7. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. AMERICAS NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 12. AMERICAS NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES NEUROMODULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 14. UNITED STATES NEUROMODULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. NEUROMODULATION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 20. NEUROMODULATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NEUROMODULATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NEUROMODULATION MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL NEUROMODULATION MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTRIC STIMULATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTRIC STIMULATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL NEUROMODULATION MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL NEUROMODULATION MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL NEUROMODULATION MARKET SIZE, BY DYSTONIA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL NEUROMODULATION MARKET SIZE, BY DYSTONIA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL NEUROMODULATION MARKET SIZE, BY ESSENTIAL TREMOR, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL NEUROMODULATION MARKET SIZE, BY ESSENTIAL TREMOR, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTROPARESIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTROPARESIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL NEUROMODULATION MARKET SIZE, BY OBSESSIVE COMPULSIVE DISORDER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL NEUROMODULATION MARKET SIZE, BY OBSESSIVE COMPULSIVE DISORDER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL NEUROMODULATION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL NEUROMODULATION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL NEUROMODULATION MARKET SIZE, BY REFRACTORY EPILEPSY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL NEUROMODULATION MARKET SIZE, BY REFRACTORY EPILEPSY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL NEUROMODULATION MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL NEUROMODULATION MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL NEUROMODULATION MARKET SIZE, BY URINARY FECAL INCONTINENCE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL NEUROMODULATION MARKET SIZE, BY URINARY FECAL INCONTINENCE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. AMERICAS NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 40. AMERICAS NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 41. AMERICAS NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 42. AMERICAS NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 43. AMERICAS NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 44. AMERICAS NEUROMODULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 45. ARGENTINA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 46. ARGENTINA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 47. ARGENTINA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 48. ARGENTINA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 49. BRAZIL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 50. BRAZIL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 51. BRAZIL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 52. BRAZIL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 53. CANADA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 54. CANADA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 55. CANADA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 56. CANADA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 57. MEXICO NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 58. MEXICO NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 59. MEXICO NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 60. MEXICO NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 61. UNITED STATES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 62. UNITED STATES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 63. UNITED STATES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 64. UNITED STATES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 65. UNITED STATES NEUROMODULATION MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 66. UNITED STATES NEUROMODULATION MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 68. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 70. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 72. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 73. AUSTRALIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 74. AUSTRALIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 75. AUSTRALIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 76. AUSTRALIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 77. CHINA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 78. CHINA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 79. CHINA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 80. CHINA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 81. INDIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 82. INDIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 83. INDIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 84. INDIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 85. INDONESIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 86. INDONESIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 87. INDONESIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 88. INDONESIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 89. JAPAN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 90. JAPAN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 91. JAPAN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 92. JAPAN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 93. MALAYSIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 94. MALAYSIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 95. MALAYSIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 96. MALAYSIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 97. PHILIPPINES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 98. PHILIPPINES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 99. PHILIPPINES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 100. PHILIPPINES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 101. SINGAPORE NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 102. SINGAPORE NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 103. SINGAPORE NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 104. SINGAPORE NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 106. SOUTH KOREA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 108. SOUTH KOREA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 109. TAIWAN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 110. TAIWAN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 111. TAIWAN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 112. TAIWAN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 113. THAILAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 114. THAILAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 115. THAILAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 116. THAILAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 117. VIETNAM NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 118. VIETNAM NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 119. VIETNAM NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 120. VIETNAM NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 121. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 122. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 123. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 127. DENMARK NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 128. DENMARK NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 129. DENMARK NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 130. DENMARK NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 131. EGYPT NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 132. EGYPT NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 133. EGYPT NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 134. EGYPT NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 135. FINLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 136. FINLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 137. FINLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 138. FINLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 139. FRANCE NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 140. FRANCE NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 141. FRANCE NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 142. FRANCE NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 143. GERMANY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 144. GERMANY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 145. GERMANY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 146. GERMANY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 147. ISRAEL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 148. ISRAEL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 149. ISRAEL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 150. ISRAEL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 151. ITALY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 152. ITALY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 153. ITALY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 154. ITALY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 155. NETHERLANDS NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 156. NETHERLANDS NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 157. NETHERLANDS NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 158. NETHERLANDS NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 159. NIGERIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 160. NIGERIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 161. NIGERIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 162. NIGERIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 163. NORWAY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 164. NORWAY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 165. NORWAY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 166. NORWAY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 167. POLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 168. POLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 169. POLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 170. POLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 171. QATAR NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 172. QATAR NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 173. QATAR NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 174. QATAR NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 175. RUSSIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 176. RUSSIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 177. RUSSIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 178. RUSSIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 179. SAUDI ARABIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 180. SAUDI ARABIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 181. SAUDI ARABIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 182. SAUDI ARABIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 183. SOUTH AFRICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 184. SOUTH AFRICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 185. SOUTH AFRICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 186. SOUTH AFRICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 187. SPAIN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 188. SPAIN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 189. SPAIN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 190. SPAIN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 191. SWEDEN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 192. SWEDEN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 193. SWEDEN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 194. SWEDEN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 195. SWITZERLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 196. SWITZERLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 197. SWITZERLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 198. SWITZERLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 199. TURKEY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 200. TURKEY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 201. TURKEY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 202. TURKEY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 203. UNITED ARAB EMIRATES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 204. UNITED ARAB EMIRATES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 205. UNITED ARAB EMIRATES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 206. UNITED ARAB EMIRATES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 207. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 208. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 209. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 210. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 211. NEUROMODULATION MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 212. NEUROMODULATION MARKET, FPNV POSITIONING MATRIX, 2023

[180 Pages Report] The Neuromodulation Market size was estimated at USD 7.76 billion in 2023 and expected to reach USD 8.61 billion in 2024, at a CAGR 11.50% to reach USD 16.62 billion by 2030.

Neuromodulation devices and therapies are designed to deliver targeted electrical, chemical, or pharmaceutical agents to the nervous system in order to modulate its activity. This technology is primarily used for the treatment of various disorders, such as chronic pain, epilepsy, Parkinson's disease, and urinary incontinence, among others. Growing incidences of chronic pain and neurological disorders have created an urgent need for neuromodulation treatments. Furthermore, increased awareness about the benefits of neuromodulation techniques, rising healthcare expenditure, and government initiatives to promote access to neurological therapies are contributing to the growing adoption of neuromodulation. However, incidences of product recall of neuromodulation devices and systems and the possibility of safety and health risks hamper the widespread growth of the technology. Additionally, the invasiveness of the therapy, coupled with strict regulations regarding the approval of medical devices, can delay the adoption of neuromodulation strategies. However, key players are researching non-invasive methods to expand the patient reach and maintain patient compliance. Developing personalized neuromodulation therapies could provide superior outcomes by catering to individual patient needs and physiology. Advances in biocompatible materials, incorporating wireless technologies to control neuromodulation devices, and utilizing big data analytics to interpret neuromodulation outcomes can provide new opportunities for the growth of the technology.

Technology: Increasing need for deep brain stimulation therapies for movement disorders and psychiatric issues

Deep brain stimulation (DBS) is a treatment for targeting movement disorders such as Parkinson's disease, essential tremor, and dystonia. It involves the implantation of electrodes within certain areas of the brain, producing electrical impulses that regulate abnormal impulses. The need for DBS is generally based on the severity and responsiveness of the condition to other treatments. Gastric stimulation, also known as gastric electrical stimulation (GES), targets the stomach's muscles and nerves and is typically used for treating obesity and gastroparesis. The need arises when patients are unresponsive to traditional treatments and require alternative interventions to manage symptoms or weight. Sacral nerve stimulation is mainly used to treat urinary and fecal incontinence. Patients with incontinence who do not respond adequately to conservative therapies may be candidates for SNS, which involves the electrical stimulation of the sacral nerve through an implantable device. Spinal cord stimulation is a treatment strategy for chronic pain situations, including failed back surgery syndrome, complex regional pain syndrome, and chronic intractable pain. SCS is chosen when other pain management therapies fail to provide sufficient relief. It involves the delivery of low-voltage electrical stimulation to the spinal cord, which then blocks pain signals before they reach the brain. Vagus nerve stimulation is primarily used for the treatment of epilepsy and depression. VNS is considered for patients who are not suitable for surgery and whose conditions are refractory to medication. The therapy delivers electrical impulses to the vagus nerve to modulate neurotransmission.

Application: Rising incidences of Parkinson's disease across the world

Chronic pain treatment is one of the primary applications of neuromodulation. Devices such as spinal cord stimulators (SCS) can provide significant pain relief by sending electrical impulses to the spinal cord. Need-based preference emerges from the limitations of pharmacological treatments and the desire to avoid long-term opioid use. Neuromodulation for dystonia often involves deep brain stimulation (DBS) to reduce involuntary muscle contractions. Patient preference relies on procedural safety and the possibility of symptom improvement when medications are not adequate. Essential tremor is commonly addressed with DBS systems targeting the thalamus to suppress tremor symptoms. The need for these systems rises among patients who are unresponsive to medications. Gastroparesis, characterized by delayed stomach emptying, can be treated with gastric electrical stimulation. Obsessive-compulsive disorder (OCD) can be managed with DBS, targeting brain regions linked to the disorder for patients who don't respond to conventional treatment. Parkinson's disease treatment through neuromodulation mainly involves DBS, which can alleviate symptoms such as rigidity, bradykinesia, and tremor. This option becomes a preference when patients experience motor symptoms despite medication. Neuromodulation for refractory epilepsy includes vagus nerve stimulation (VNS) and responsive neurostimulation (RNS). These therapies are indicated for patients not suitable for surgery or those with intractable epilepsy. Treatment-resistant depression (TRD) can benefit from vagus nerve stimulation, which helps in modulating mood and emotional regulation pathways. Preference arises when multiple antidepressants fail to provide adequate clinical benefits. Sacral neuromodulation is effective for managing urinary and fecal incontinence, with acceptance increasing due to limited effective pharmaceutical options.

Regional Insights

The Americas region, particularly the U.S. and Canada, is characterized by the presence of a robust healthcare architecture and favorable reimbursement and insurance policies, which has shaped the adoption of neuromodulation technologies. Additionally, the awareness regarding neurological disorders and mental health issues is high in this region, thereby driving the recognition of the technology among patients. The patient landscape reflects a preference for innovative, FDA-approved treatments and a willingness to adopt new technologies. The Americas region exhibits a robust patent landscape with ongoing research and substantial investments in the neuromodulation space, as companies and research institutions aim to advance the efficacy and scope of neuromodulation therapies. In the European Union, increased life expectancy and favorable reimbursement policies are significant factors driving the need for the neuromodulation market. Patient needs are centered around the management of chronic conditions prevalent in an aging population, and customer purchasing behavior is influenced by the healthcare coverage provided by public health systems. There is a focus on creating common standards and regulations across the EU to facilitate market access and ensure patient safety. The EU is characterized by stringent healthcare regulations, which have fuelled several innovations to improve the safety and precision of neuromodulation technologies. The increasing incidences of neurological diseases in countries such as India and China and a rapidly aging population in Japan have augmented the need for neuromodulation therapies. Health awareness and government initiatives to advance the healthcare infrastructure can create a robust ground for the growth of neuromodulation in the APAC region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Neuromodulation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Neuromodulation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Neuromodulation Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, BioControl by Merck, BioElectronics Corporation, Boston Scientific Corporation, Dr Reddys Laboratories Limited, EndoStim, Inc., Galderma S.A., GrayMatters Health, Impulse Dynamics, Livanova, Mainstay Medical, Medtronic PLC, MicroTransponde, NeuroMetrix, Neuronetics, Inc., NeuroPace, Inc., NeuroSigma, Inc., Nevro Corp., Saluda Medical, SceneRay Corporation, Limited, Soterix Medical, and Synapse Biomedical.

Market Segmentation & Coverage

This research report categorizes the Neuromodulation Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Technology
  • Deep Brain Stimulation
  • Gastric Stimulation
  • Sacral Nerve Stimulation
  • Spinal Cord Stimulation
  • Vagus Nerve Stimulation

• Application
  • Chronic Pain
  • Dystonia
  • Essential Tremor
  • Gastroparesis
  • Obsessive Compulsive Disorder
  • Parkinson's Disease
  • Refractory Epilepsy
  • Treatment Resistant Depression
  • Urinary Fecal Incontinence

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Neuromodulation Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Neuromodulation Market?

3. What are the technology trends and regulatory frameworks in the Neuromodulation Market?

4. What is the market share of the leading vendors in the Neuromodulation Market?

5. Which modes and strategic moves are suitable for entering the Neuromodulation Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in the aging population across the world and prevalence of neurological disorders
    • 5.1.1.2. Research initiatives and clinical trials for neurostimulation systems and neuromodulation solutions
    • 5.1.1.3. Government initiatives to expand access to therapies for neurological diseases and disorders
  • 5.1.2. Restraints
    • 5.1.2.1. Incidences of product recall of neuromodulation and neurostimulation devices or systems
  • 5.1.3. Opportunities
    • 5.1.3.1. Innovations to optimize the efficiency and safety of neuromodulation strategies
    • 5.1.3.2. Ongoing approvals for neuromodulation devices and treatments across the world
  • 5.1.4. Challenges
    • 5.1.4.1. Invasiveness and technical limitations of the technology
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Increasing need for deep brain stimulation therapies for movement disorders and psychiatric issues
  • 5.2.2. Application: Rising incidences of Parkinson's disease across the world
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Neuromodulation Market, by Technology

• 6.1. Introduction
• 6.2. Deep Brain Stimulation
• 6.3. Gastric Stimulation
• 6.4. Sacral Nerve Stimulation
• 6.5. Spinal Cord Stimulation
• 6.6. Vagus Nerve Stimulation

7. Neuromodulation Market, by Application

• 7.1. Introduction
• 7.2. Chronic Pain
• 7.3. Dystonia
• 7.4. Essential Tremor
• 7.5. Gastroparesis
• 7.6. Obsessive Compulsive Disorder
• 7.7. Parkinson's Disease
• 7.8. Refractory Epilepsy
• 7.9. Treatment Resistant Depression
• 7.10. Urinary Fecal Incontinence

8. Americas Neuromodulation Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Neuromodulation Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Neuromodulation Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. GrayMatters Health Launches New FDA-Cleared Self-Neuromodulation PTSD Therapy in the United States
  • 11.3.2. Dr. Reddy's Unveils Wearable for Migraine Management in India
  • 11.3.3. Galderma Unveils Bold Ambition in Neuromodulation at Liquid Live Event
• 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

• 12.1. Key Company Profiles
• 12.2. Key Product Portfolio